PDPN is aberrantly overexpressed across various malignancies—including hepatocellular carcinoma (6, 7), glioma (8, 9), breast cancer (10), and lung squamous cell carcinoma (11, 12)—where it actively drives tumor initiation, progression, and metastatic spread. Here, PDPN is linked to neoplasm.